Logo image of CNTX

CONTEXT THERAPEUTICS INC (CNTX) Stock Fundamental Analysis

NASDAQ:CNTX - Nasdaq - US21077P1084 - Common Stock - Currency: USD

0.814  +0.02 (+3.04%)

After market: 0.7855 -0.03 (-3.5%)

Fundamental Rating

3

Overall CNTX gets a fundamental rating of 3 out of 10. We evaluated CNTX against 194 industry peers in the Pharmaceuticals industry. CNTX has a great financial health rating, but its profitability evaluates not so good. CNTX has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

CNTX had negative earnings in the past year.
In the past year CNTX has reported a negative cash flow from operations.
In the past 5 years CNTX reported 4 times negative net income.
CNTX had a negative operating cash flow in each of the past 5 years.
CNTX Yearly Net Income VS EBIT VS OCF VS FCFCNTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2019 2020 2021 2022 2023 0 -10M -20M -30M

1.2 Ratios

CNTX has a Return On Assets (-34.93%) which is in line with its industry peers.
CNTX has a better Return On Equity (-35.96%) than 62.16% of its industry peers.
Industry RankSector Rank
ROA -34.93%
ROE -35.96%
ROIC N/A
ROA(3y)-69.55%
ROA(5y)-231.77%
ROE(3y)-88.74%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CNTX Yearly ROA, ROE, ROICCNTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2019 2020 2021 2022 2023 0 1K -1K -2K

1.3 Margins

CNTX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CNTX Yearly Profit, Operating, Gross MarginsCNTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2019 2020 2021 2022 2023

More info and screens

9

2. Health

2.1 Basic Checks

The number of shares outstanding for CNTX remains at a similar level compared to 1 year ago.
There is no outstanding debt for CNTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CNTX Yearly Shares OutstandingCNTX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2019 2020 2021 2022 2023 5M 10M 15M 20M
CNTX Yearly Total Debt VS Total AssetsCNTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2019 2020 2021 2022 2023 20M 40M 60M

2.2 Solvency

An Altman-Z score of 12.82 indicates that CNTX is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 12.82, CNTX belongs to the best of the industry, outperforming 87.57% of the companies in the same industry.
CNTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 12.82
ROIC/WACCN/A
WACCN/A
CNTX Yearly LT Debt VS Equity VS FCFCNTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2019 2020 2021 2022 2023 0 20M -20M 40M

2.3 Liquidity

A Current Ratio of 36.91 indicates that CNTX has no problem at all paying its short term obligations.
With an excellent Current ratio value of 36.91, CNTX belongs to the best of the industry, outperforming 98.38% of the companies in the same industry.
CNTX has a Quick Ratio of 36.91. This indicates that CNTX is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of CNTX (36.91) is better than 98.38% of its industry peers.
Industry RankSector Rank
Current Ratio 36.91
Quick Ratio 36.91
CNTX Yearly Current Assets VS Current LiabilitesCNTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2019 2020 2021 2022 2023 20M 40M 60M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 30.00% over the past year.
EPS 1Y (TTM)30%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%40.54%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, CNTX will show a quite strong growth in Earnings Per Share. The EPS will grow by 8.89% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y60.55%
EPS Next 2Y30.47%
EPS Next 3Y17.98%
EPS Next 5Y8.89%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CNTX Yearly Revenue VS EstimatesCNTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M 500M
CNTX Yearly EPS VS EstimatesCNTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 -4 -6 -8

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CNTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CNTX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CNTX Price Earnings VS Forward Price EarningsCNTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CNTX Per share dataCNTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1

4.3 Compensation for Growth

CNTX's earnings are expected to grow with 17.98% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y30.47%
EPS Next 3Y17.98%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CNTX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CONTEXT THERAPEUTICS INC

NASDAQ:CNTX (2/21/2025, 8:10:27 PM)

After market: 0.7855 -0.03 (-3.5%)

0.814

+0.02 (+3.04%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-06 2024-11-06/amc
Earnings (Next)N/A N/A
Inst Owners76.4%
Inst Owner ChangeN/A
Ins Owners1.45%
Ins Owner Change0%
Market Cap61.05M
Analysts81.67
Price Target7.22 (786.98%)
Short Float %3.08%
Short Ratio4.11
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-28.85%
Min EPS beat(2)-105.41%
Max EPS beat(2)47.71%
EPS beat(4)2
Avg EPS beat(4)-6.65%
Min EPS beat(4)-105.41%
Max EPS beat(4)48.75%
EPS beat(8)3
Avg EPS beat(8)-21.89%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-3.96%
PT rev (3m)-7.1%
EPS NQ rev (1m)-63.76%
EPS NQ rev (3m)-68.73%
EPS NY rev (1m)-9.99%
EPS NY rev (3m)-68.99%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.73
P/tB 0.73
EV/EBITDA N/A
EPS(TTM)-0.91
EYN/A
EPS(NY)-0.45
Fwd EYN/A
FCF(TTM)-0.23
FCFYN/A
OCF(TTM)-0.23
OCFYN/A
SpS0
BVpS1.12
TBVpS1.12
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -34.93%
ROE -35.96%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-69.55%
ROA(5y)-231.77%
ROE(3y)-88.74%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 73.27%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 36.91
Quick Ratio 36.91
Altman-Z 12.82
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)30%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%40.54%
EPS Next Y60.55%
EPS Next 2Y30.47%
EPS Next 3Y17.98%
EPS Next 5Y8.89%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-47.81%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-38.79%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-15.49%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-15.76%
OCF growth 3YN/A
OCF growth 5YN/A